Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
399 studies found for:    "Myelofibrosis"
Show Display Options
RSS Create an RSS feed from your search for:
"Myelofibrosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: SAR302503 (TG101348)
2 Recruiting Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Condition: Myelofibrosis
Intervention:
3 Active, not recruiting Lenalidomide for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Lenalidomide;   Drug: Prednisone
4 Active, not recruiting Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Peginterferon alfa-2a
5 Recruiting JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Ruxolotinib
6 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
7 Not yet recruiting Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Other: Hematopoietic Stem Cell Transplant
8 Completed
Has Results
Ph II Study of Azacitidine in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Azacitidine
9 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
10 Completed
Has Results
A Phase II Study of CC-5013 in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: CC-5013
11 Terminated
Has Results
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
12 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
13 Recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires
14 Recruiting A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INCB050465;   Drug: Ruxolitinib
15 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
16 Recruiting Quantitative MRI for Myelofibrosis
Condition: Myelofibrosis
Intervention: Procedure: T1 Weighted MRI (magnetic resonance imaging)
17 Active, not recruiting
Has Results
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
18 Suspended Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg);   Drug: Imetelstat 4.7 mg/kg
19 Recruiting Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: PIM447;   Drug: Ruxolitinib;   Drug: LEE011
20 Active, not recruiting Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: A: Fludarabine + Busulphan;   Drug: B: Fludarabine + Thiotepa

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.